Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue (GHS) and, more specifically, a growth hormone-releasing peptide (GHRP). Since its identification in the 1990s, it has become one of the most frequently referenced peptides in growth-hormone-axis research, largely because of a property that sets it apart from earlier GHRPs: receptor selectivity.

This guide breaks down what the ipamorelin peptide is, how it interacts with the body’s signaling pathways, and what the current body of research indicates — all framed for the research and laboratory context in which this compound is studied.

What Is Ipamorelin?

Ipamorelin belongs to the growth hormone-releasing peptide family, a class of compounds designed to mimic the action of ghrelin, the body’s endogenous “hunger hormone” that also plays a central role in stimulating growth hormone (GH) release from the pituitary gland.

Structurally, ipamorelin is a five-amino-acid chain engineered for stability and receptor affinity. Researchers frequently compare it to earlier-generation secretagogues like GHRP-6 and GHRP-2, both of which are also studied for their GH-releasing properties but come with a broader, less selective hormonal response.

Mechanism of Action: How Ipamorelin Signals the Pituitary

Ipamorelin research centers on its interaction with the growth hormone secretagogue receptor (GHS-R1a), the same receptor ghrelin binds to. When this receptor is activated in the pituitary gland, it triggers a cascade that results in a pulsatile release of growth hormone into the bloodstream — mirroring the body’s natural GH release pattern rather than producing a constant, flat elevation.

What distinguishes ipamorelin in the literature is its apparent selectivity. Several published studies report that ipamorelin stimulates GH release without meaningfully elevating cortisol, prolactin, or adrenocorticotropic hormone (ACTH) — hormones that earlier GHRPs like GHRP-6 tend to raise alongside GH. This selectivity is a primary reason ipamorelin is such a heavily referenced compound in comparative secretagogue research.

Ipamorelin vs. Other Growth Hormone Secretagogues

Researchers studying the GHRP family often position ipamorelin against three comparison points:

• GHRP-6: Known for strong GH stimulation but also for triggering appetite (via ghrelin-receptor cross-talk) and modest cortisol/prolactin elevation.
• GHRP-2: Potent GH-releasing activity, generally considered less selective than ipamorelin in receptor-binding studies.
• GHRH analogs (e.g., CJC-1295, Tesamorelin): Act on a different receptor (GHRH-R) and are frequently studied in combination with ipamorelin, since the two pathways are complementary rather than redundant.

What the Research Shows

Preclinical and early-phase research on ipamorelin has explored its role in growth-hormone-axis regulation, its comparative selectivity profile against other secretagogues, and its potential relevance to body composition and bone metabolism studies. It’s also frequently used as a reference compound in receptor-binding assays because of its well-characterized selectivity for GHS-R1a.

As with all research peptides in this class, findings are drawn from laboratory, animal, and early clinical study data. Ipamorelin is not an FDA-approved drug for human use, and any research involving it should follow institutional protocols, biosafety guidelines, and applicable regulations for research chemicals.

Stability, Storage & Handling

Like most peptides, ipamorelin is typically supplied as a lyophilized (freeze-dried) powder to preserve stability during shipping and storage. Once reconstituted with bacteriostatic water for laboratory use, proper cold-chain storage becomes essential to preserve peptide integrity for the duration of a research protocol.

For a full walkthrough of proper reconstitution technique, see our companion guide on how to reconstitute peptides.

Frequently Asked Questions

What research category does ipamorelin fall into?

Ipamorelin is studied as a growth hormone-releasing peptide (GHRP) and growth hormone secretagogue, a subclass of compounds that interact with the GHS-R1a receptor.

How is ipamorelin different from GHRP-6 or GHRP-2 in the literature?

Comparative studies point to ipamorelin’s higher receptor selectivity — GH release without the notable cortisol, prolactin, or ACTH elevation associated with older-generation GHRPs.

Is ipamorelin approved for human use?

No. Ipamorelin is not FDA-approved for human or animal use. It is sold and studied strictly as a research chemical, intended for laboratory research by qualified professionals.

Explore our full peptide research catalog, including ipamorelin, for laboratory use.

https://galaxypeptide.com/product-category/peptides/